AU2015256178B2 - Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer - Google Patents

Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer Download PDF

Info

Publication number
AU2015256178B2
AU2015256178B2 AU2015256178A AU2015256178A AU2015256178B2 AU 2015256178 B2 AU2015256178 B2 AU 2015256178B2 AU 2015256178 A AU2015256178 A AU 2015256178A AU 2015256178 A AU2015256178 A AU 2015256178A AU 2015256178 B2 AU2015256178 B2 AU 2015256178B2
Authority
AU
Australia
Prior art keywords
resveratrol
ursolic acid
administered
diabetes
res
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015256178A
Other languages
English (en)
Other versions
AU2015256178A1 (en
Inventor
Jacob JUNCO
Huiyun LIANG
Sara REYNA
Thomas J. Slaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2015256178A1 publication Critical patent/AU2015256178A1/en
Application granted granted Critical
Publication of AU2015256178B2 publication Critical patent/AU2015256178B2/en
Priority to AU2020203419A priority Critical patent/AU2020203419B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015256178A 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer Ceased AU2015256178B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203419A AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988859P 2014-05-05 2014-05-05
US61/988,859 2014-05-05
PCT/US2015/029224 WO2015171598A1 (en) 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203419A Division AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Publications (2)

Publication Number Publication Date
AU2015256178A1 AU2015256178A1 (en) 2016-11-24
AU2015256178B2 true AU2015256178B2 (en) 2020-02-27

Family

ID=54392898

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015256178A Ceased AU2015256178B2 (en) 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
AU2020203419A Ceased AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203419A Ceased AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Country Status (6)

Country Link
US (7) US10155003B2 (enExample)
EP (1) EP3139910B1 (enExample)
JP (2) JP6716468B2 (enExample)
AU (2) AU2015256178B2 (enExample)
MY (1) MY181685A (enExample)
WO (1) WO2015171598A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155003B2 (en) * 2014-05-05 2018-12-18 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
WO2017080958A1 (en) * 2015-11-13 2017-05-18 Unilever Plc Composition for hair follicle growth
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN109248170B (zh) 2017-07-13 2023-10-03 华东理工大学 靶向于pd-1的皂苷类化合物及其应用
EP3681507B8 (en) 2017-09-13 2024-03-13 Emmyon, Inc. Ursolic acid morpholine and diethanolamine salts
EP4433174A4 (en) * 2021-11-18 2025-10-22 Univ Texas COMBINATIONS OF CURCUMIN AND URSOLIC ACID AND THEIR USES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
JP5339373B2 (ja) * 2006-07-14 2013-11-13 ディーエスエム アイピー アセッツ ビー．ブイ． 組成物および炎症障害の治療、共治療または予防のためのその使用
MY154869A (en) * 2007-01-16 2015-08-14 Ipintl Llc Composition for treating metabolic syndrome
CN101032564B (zh) * 2007-02-28 2011-03-23 天津津酒集团有限公司 调节血脂养生酒及其制备方法
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
KR101819699B1 (ko) * 2010-04-12 2018-01-17 리아타 파마슈티컬즈, 아이엔씨. 항산화성 염증 조절제를 이용하여 비만을 치료하는 방법
US9393221B2 (en) * 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage
WO2014014530A1 (en) 2012-07-17 2014-01-23 Mylari Banavara L Ursolic acid salts for treating diabetes and obesity
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
US10155003B2 (en) * 2014-05-05 2018-12-18 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
NZ728488A (en) * 2014-07-29 2023-03-31 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JUNCO, JJ et al., "Resveratrol and P-glycoprotein Inhibitors Enhance the Anti-skin Cancer Effects of Ursolic Acid.", Molecular Cancer Research, (2013-12), vol. 11, no. 12., ISSN 1541-7786, pages 1 - 17 *
MACARULLA M T ET AL, "Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet.", JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY DEC 2009, (2009-12), vol. 65, no. 4, ISSN 1138-7548, pages 369 - 376 *
STEVEN D. KUNKEL ET AL, PLOS ONE, (2012-06-20), vol. 7, no. 6, doi:10.1371/journal.pone.0039332, page e39332 *

Also Published As

Publication number Publication date
US20210252016A1 (en) 2021-08-19
US20170056414A1 (en) 2017-03-02
AU2020203419B2 (en) 2021-05-13
US10583145B2 (en) 2020-03-10
US11090311B2 (en) 2021-08-17
EP3139910A4 (en) 2017-11-29
JP2020147590A (ja) 2020-09-17
US11166962B2 (en) 2021-11-09
EP3139910B1 (en) 2019-11-27
WO2015171598A1 (en) 2015-11-12
EP3139910A1 (en) 2017-03-15
US10155003B2 (en) 2018-12-18
US11642354B2 (en) 2023-05-09
JP2017514858A (ja) 2017-06-08
US11684626B2 (en) 2023-06-27
US20220023241A1 (en) 2022-01-27
JP6716468B2 (ja) 2020-07-01
AU2020203419A1 (en) 2020-06-11
US20200323879A1 (en) 2020-10-15
AU2015256178A1 (en) 2016-11-24
US11690851B2 (en) 2023-07-04
US20190192537A1 (en) 2019-06-27
US20200330480A1 (en) 2020-10-22
US20220226347A1 (en) 2022-07-21
MY181685A (en) 2020-12-31

Similar Documents

Publication Publication Date Title
US11684626B2 (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
Calvano et al. Dietary berries, insulin resistance and type 2 diabetes: An overview of human feeding trials
Verma et al. Obesity and diabetes: an update
Christiansen et al. The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon
US20240325410A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
Fan et al. HDAC11 deletion reduces fructose-induced cardiac dyslipidemia, apoptosis and inflammation by attenuating oxidative stress injury
US20250000878A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
Rafe et al. Preventive role of resveratrol against inflammatory cytokines and related diseases
Yamashita et al. Cacao liquor procyanidins prevent postprandial hyperglycaemia by increasing glucagon-like peptide-1 activity and AMP-activated protein kinase in mice
Noori et al. Role of natural mTOR inhibitors in treatment of diabetes mellitus
US20140148399A1 (en) Compositions and methods for treating or ameliorating obesity or for reducing diabetic hypercholesterolemia
Park et al. Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model
US20250205263A1 (en) Oral composition comprising b-escin and the use thereof
Carneiro et al. Tissue‐specific roles of mitochondrial unfolded protein response during obesity
Landrier et al. Tomatoes and lycopene: Inflammatory modulator effects
Chomsy et al. Decaffeinated green tea and green coffee extracts as metformin’s add-on enhance metabolic syndrome risk factors and improve the cardiac insulin-gene-related pathway
Jain et al. Nutraceuticals and Obesity: Strategies for Weight Management
US20240358055A1 (en) Dietary supplements for weight management and glycemic control
Hastings The Effects of Estrogenic Compounds on Adipogenesis Via PPARγ and Canonical Wnt Signaling
Li EFFECTS OF GRAPE POMACE ON METABOLIC SYNDROME: DIABETES AND OBESITY
Stahel Effects of selenized casein and carbohydrate components of milk on insulin sensitivity in rats
Virga et al. Incretin-Based Pharmacotherapy for Reducing Prostate Cancer Risk
Cyclophosphamide-Induced Poster Communications

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 05 MAY 2021 TO 05 DEC 2021 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 05 DEC 2021

MK14 Patent ceased section 143(a) (annual fees not paid) or expired